Skip to main content
. 2022 Jul 22;41(1):107–116. doi: 10.1200/JCO.22.00430

FIG 3.

FIG 3.

Forest plots of benefit from veliparib-throughout versus placebo arms regarding PFS according to homologous recombination (HR) status in patients with (A) favorable KELIM or (B) unfavorable KELIM treated with primary debulking surgery. HRD, homologous recombination deficiency; HRP, homologous recombination proficiency; KELIM, elimination rate constant K; PFS, progression-free survival; VEL, veliparib.